Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Robbins

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residueT M Clay, M C Custer, M D McKee, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionY Kawakami, S Eliyahu, C H Delgado, et al.
Cancer Research|January 8, 2000
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyteM I Nishimura, D Avichezer, M C Custer, et al.
Journal of Immunological Methods|March 10, 1997
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1Y Kawakami, J K Battles, T Kobayashi, et al.
Cancer Research|June 11, 1999
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogensK R Irvine, M R Parkhurst, E P Shulman, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residueT M Clay, M C Custer, M D McKee, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 1994
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejectionY Kawakami, S Eliyahu, C H Delgado, et al.
Cancer Research|January 8, 2000
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyteM I Nishimura, D Avichezer, M C Custer, et al.
Journal of Immunological Methods|March 10, 1997
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1Y Kawakami, J K Battles, T Kobayashi, et al.
Cancer Research|June 11, 1999
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogensK R Irvine, M R Parkhurst, E P Shulman, et al.
Pageof 5